These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond. Boyle DP; Zembower TR Urol Clin North Am; 2015 Nov; 42(4):493-505. PubMed ID: 26475946 [TBL] [Abstract][Full Text] [Related]
3. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases. Mushtaq S; Vickers A; Woodford N; Livermore DM J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319 [TBL] [Abstract][Full Text] [Related]
4. [Approach to directed therapy after knowledge of the isolate: carbapenemase-producing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii]. Martínez JA Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():31-4. PubMed ID: 27608310 [TBL] [Abstract][Full Text] [Related]
5. [Broad-spectrum beta-lactamases in Gram-negative bacteria]. Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424 [TBL] [Abstract][Full Text] [Related]
6. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338 [TBL] [Abstract][Full Text] [Related]
7. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ; J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial resistance among and therapeutic options against gram-negative pathogens. Rahal JJ Clin Infect Dis; 2009 Aug; 49 Suppl 1():S4-S10. PubMed ID: 19619021 [TBL] [Abstract][Full Text] [Related]
9. The current state of multidrug-resistant gram-negative bacilli in North America. Nicasio AM; Kuti JL; Nicolau DP Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969 [TBL] [Abstract][Full Text] [Related]
10. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains. Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921 [TBL] [Abstract][Full Text] [Related]
11. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review. Nørgaard SM; Jensen CS; Aalestrup J; Vandenbroucke-Grauls CMJE; de Boer MGJ; Pedersen AB Antimicrob Resist Infect Control; 2019; 8():170. PubMed ID: 31709047 [TBL] [Abstract][Full Text] [Related]
12. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management. Kaye KS; Pogue JM Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481 [TBL] [Abstract][Full Text] [Related]
14. Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms. Kois AK; Nicolau DP; Kuti JL Curr Opin Infect Dis; 2020 Dec; 33(6):482-494. PubMed ID: 33009141 [TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study. Kiratisin P; Chongthaleong A; Tan TY; Lagamayo E; Roberts S; Garcia J; Davies T Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743 [TBL] [Abstract][Full Text] [Related]
16. Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings? Apisarnthanarak A; Hsu LY; Khawcharoenporn T; Mundy LM Expert Rev Anti Infect Ther; 2013 Feb; 11(2):147-57. PubMed ID: 23409821 [TBL] [Abstract][Full Text] [Related]
17. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. Burgess DS; Frei CR J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664 [TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of Carbapenem Resistance Mechanisms Among Gram-Negative Pathogens in Lebanon: Results of the First Cross-Sectional Countrywide Study. Hammoudi Halat D; Moubareck CA; Sarkis DK Microb Drug Resist; 2017 Sep; 23(6):733-743. PubMed ID: 28080212 [TBL] [Abstract][Full Text] [Related]